INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Argenx SE - ARGX

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the“Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at ... or 646-581-9980, ext. 7980.

The investigation concerns whether argenx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 30, 2025, the U.S. Food and Drug Administration (“FDA”) issued an alert on a potential signal of serious risks associated with argenx's Vyvgart Hytrulo product, stating that the treatment has a potential risk of“severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy” based on reports to the FDA Adverse Event Reporting System. The alert also said that the“FDA is evaluating the need for regulatory action.”

On this news, argenx's American Depositary Share (“ADS”) price fell $8.92 per ADS, or 1.59%, to close at $551.22 per ADS on June 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980

MENAFN06072025004107003653ID1109765637